P
Philip Brohawn
Researcher at MedImmune
Publications - 70
Citations - 3643
Philip Brohawn is an academic researcher from MedImmune. The author has contributed to research in topics: Cancer & Durvalumab. The author has an hindex of 24, co-authored 69 publications receiving 2906 citations.
Papers
More filters
Journal ArticleDOI
Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie,Munther A. Khamashta,Joan T. Merrill,Victoria P. Werth,Kenneth C. Kalunian,Philip Brohawn,G. Illei,Jorn Drappa,L. Wang,Stephen Yoo +9 more
TL;DR: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE).
Journal ArticleDOI
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Brandon W. Higgs,Zheng Liu,Barbara White,Wei Zhu,Wendy I. White,Chris Morehouse,Philip Brohawn,Peter A. Kiener,Laura Richman,David Fiorentino,Steven A. Greenberg,Bahija Jallal,Yihong Yao +12 more
TL;DR: The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.
Journal ArticleDOI
Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus
Yihong Yao,Laura Richman,Brandon W. Higgs,Christopher Morehouse,Melissa de los Reyes,Philip Brohawn,Jianliang Zhang,Barbara White,Anthony J. Coyle,Peter A. Kiener,Bahija Jallal +10 more
TL;DR: Anti-IFNalpha mAb can neutralize overexpression of IFNalpha/beta-inducible genes in whole blood and lesional skin from SLE patients and has profound effects on signaling pathways that may be downstream of IFnalpha in SLE.
Journal ArticleDOI
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Suzanne Mosely,John E. Prime,Richard C.A. Sainson,Jens-Oliver Koopmann,Dennis Wang,Danielle Greenawalt,Miika Ahdesmaki,Rebecca Leyland,Stefanie R. Mullins,Luciano Pacelli,Danielle Marcus,Judith Anderton,Amanda Watkins,Jane Coates Ulrichsen,Philip Brohawn,Brandon W. Higgs,Matthew McCourt,Hazel Jones,James Harper,Michelle Morrow,Viia Valge-Archer,Ross Stewart,Simon J. Dovedi,Robert W. Wilkinson +23 more
TL;DR: Characterization of murine syngeneic tumor models highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of immunotherapies as well as combinations with targeted therapies in vivo.
Journal ArticleDOI
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Brandon W. Higgs,Wei Zhu,Chris Morehouse,Wendy I. White,Philip Brohawn,Xiang Guo,Marlon Rebelatto,Chenxiong Le,Anthony A. Amato,David Fiorentino,Steven A. Greenberg,Jorn Drappa,Laura Richman,Warren Greth,Bahija Jallal,Yihong Yao +15 more
TL;DR: Sifalimumab suppressed the IFNGS in blood and muscle tissue in myositis patients, consistent with this molecule's mechanism of action with a positive correlative trend between target neutralisation and clinical improvement.